Top news
Pfizer, BioNTech ask FDA for full approval of Covid-19 vaccine
By Erika Edwards
Why we shouldn't panic about the millions who missed their second vaccine dose—yet
By Maya Wei-Haas
India's vaccinations plummet as coronavirus infections soar
By Krishna N. Das
Next Generation of Covid-19 Vaccines Could Be Pill or Spray
By Peter Loftus & Gregory Zuckerman
All coverage
Your COVID vaccine booster might be a patch or a pill. Or it might come with your flu shot.
By Alexander Tin
Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues
By Kevin Breuninger
BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says
By Noah Higgins-Dunn
Pfizer-BioNTech Vaccine is Highly Effective Against Variants, Studies Find (Published 2021)
By Emily Anthes
How the Moderna, AstraZeneca, Pfizer and other Covid vaccines compare
By Annelies Gartner, Anne Gulland & Jennifer Rigby
Pfizer to seek authorization for Covid-19 vaccine for children ages 2 to 11 in September
By Naomi Thomas
Pfizer Seeks Full FDA Approval For COVID-19 Vaccine
By Emma Bowman
Pfizer sees robust COVID-19 vaccine demand for years, $26 bln in 2021 sales
By Michael Erman & Manas Mishra
Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine
By Berkeley Lovelace, Berkeley Lovelace Jr. & Dawn Kopecki
F.D.A. Set to Authorize Pfizer Vaccine for Adolescents by Early Next Week (Published 2021)
By Apoorva Mandavilli, Sharon LaFraniere & Noah Mercer Weiland
Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine (Published 2021)
By Rebecca Robbins & Peter S. Goodman
COVID-19 vaccines and kids: What parents should know
By Katie Kindelan